Date | Company | Who recommends | Recommendation | Target price |
---|---|---|---|---|
Abbott Laboratories | Barclays | Buy | 52 | |
AbbVie Inc. | UBS | Buy | 78 | |
Aetna Inc. | BofA/Merrill | Buy | 162 | |
Alexion Pharmaceuticals, Inc. | UBS | Buy | 223 | |
Allergan plc | Deutsche Bank | Buy | 342 | |
Amgen Inc. | Deutsche Bank | Buy | 180 | |
Anthem, Inc. | RBC Capital Mkts | Buy | 198 | |
Becton, Dickinson and Company | Deutsche Bank | Buy | 167 | |
Biogen Inc. | Bernstein | Buy | 360 | |
Boston Scientific Corporation | Deutsche Bank | Buy | 22 | |
Bristol-Myers Squibb Company | Morgan Stanley | Buy | 80 | |
Celgene Corporation | UBS | Buy | 156 | |
Cigna Corp. | Barclays | Buy | 156 | |
CVS Health Corporation | Deutsche Bank | Buy | 118 | |
DaVita HealthCare Partners Inc. | RBC Capital Mkts | Buy | 83 | |
DENTSPLY International Inc. | Morgan Stanley | Buy | 70 | |
Edwards Lifesciences Corp. | RBC Capital Mkts | Buy | 160 | |
Eli Lilly and Company | BofA/Merrill | Buy | 90 | |
Endo International plc | Deutsche Bank | Buy | 88 | |
Express Scripts Holding Company | RBC Capital Mkts | Buy | 95 |